mt101-5
Small moleculeexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jul 11, 2022 (NCT05844787)
Timeline
Indications
Studied for
Mechanism of action
- Alpha-synucleinINHIBITOR
SNCA inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06175767 | Phase 2 | Jan 31, 2024 | Mthera Pharma Co., Ltd. |
| NCT05844787 | Phase 1 | Jul 11, 2022 | Amarex Clinical Research, Mthera Pharma Co., Ltd. |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Mthera Pharma Co., Ltd. | For profit | 2 | 2 | 2 | 2022 |
| Amarex Clinical Research | For profit | 1 | 0 | 1 | 2022 |
2 organizations
Page 1 / 1